Compare REGN & CL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | CL |
|---|---|---|
| Founded | 1988 | 1806 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 64.0B |
| IPO Year | 1991 | N/A |
| Metric | REGN | CL |
|---|---|---|
| Price | $798.79 | $96.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 17 |
| Target Price | ★ $812.57 | $95.06 |
| AVG Volume (30 Days) | 885.1K | ★ 7.4M |
| Earning Date | 01-30-2026 | 01-30-2026 |
| Dividend Yield | 0.47% | ★ 2.15% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 41.48 | 2.63 |
| Revenue | $14,342,900,000.00 | ★ $20,382,000,000.00 |
| Revenue This Year | $10.39 | $7.23 |
| Revenue Next Year | $9.73 | $3.29 |
| P/E Ratio | ★ $19.36 | $36.76 |
| Revenue Growth | 0.99 | ★ 1.40 |
| 52 Week Low | $476.49 | $74.55 |
| 52 Week High | $821.11 | $100.18 |
| Indicator | REGN | CL |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 80.30 |
| Support Level | $745.07 | $93.15 |
| Resistance Level | $790.00 | $98.13 |
| Average True Range (ATR) | 24.14 | 1.93 |
| MACD | 3.45 | 0.40 |
| Stochastic Oscillator | 95.97 | 89.27 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one-fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.